Episode 42 Nanotechnology in Oil & Gas: The Future of Drilling Innovation with Vitaly Sergeev

Episode 42 Nanotechnology in Oil & Gas: The Future of Drilling Innovation with Vitaly Sergeev

Phil sits down with Vitaly Sergeev, founder of Nanoborne, to explore what happens when cutting-edge nanotechnology meets one of the world's most risk-averse industries. Vitaly breaks down why oil & gas resists change, how flow control is reshaping field development, and what it took to spend six years turning a lab-built nanoemulsion into a real market product. They also cover the challenges of breaking into the conservative US energy market and how AI and machine learning are helping them scale and survive long adoption cycles.

Episode 41 Bridging the Gap: Navigating Energy Investments in Latin America with Warren Levy

Warren Levy, a longtime energy sector professional, reflects on re-entering the field to connect investors with Latin American opportunities. He covers the region's investment landscape, geopolitical influences, cultural considerations, and the link between energy policy and socioeconomic progress. The discussion also explores community engagement, AI's growing role in energy, and biodiversity as a meaningful project success metric.

Episode 40 Inside Financial Compliance: AI, Regulation & the SEC Perspective with Ahmed Abdul-Jaleel

Former SEC regulator Ahmed Abdul-Jaleel joins Phil to discuss his move to Empower Investments, the realities of compliance in a changing regulatory landscape, and how AI is transforming financial services. From risk management and governance to AI-powered research, oversight, and training, this episode explores the future of compliance from both a regulator’s and operator’s perspective.

Episode 39 Flipping the Script: Making Grass-Fed Beef Accessible to All with Chris Kerston

Co-founder of Origin Provisions Chris Kerston explains how rising beef prices, a shrinking US cattle herd, and shifting consumer values pushed him to build a grass-fed brand for Middle America, one that trades premium margins for scale, transparency, and shelf space in everyday grocery stores.

Episode 38 Why Cancer Keeps Winning: Randall Riggs on drug failure, mutation, and limits of progress

30 years in pharma and one approved drug says everything. Randall B. Riggs breaks down why cancer resists even the best science, how mutation outpaces static treatments, and why resilience matters more than breakthroughs. Progress is real, but the odds, funding gaps, and biology keep the fight brutally uneven.